Patient Support Helpline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.


Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

ASCO Adds New Combos for Metastatic Noncastrate Prostate Cancer

Use of androgen deprivation therapy (ADT) in combination with docetaxel (Taxotere) or abiraterone (Zytiga) in newly diagnosed cases of metastatic noncastrate prostate cancer (mNCPC) is recommended in recently updated American Society of Clinical Oncology (ASCO) guidelines. Historically, mNCPC has been treated with ADT alone until progression.

Read more.

source: Ariela Katz - OncLive

Together, we can END prostate cancer.

Donate Today